| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/01/2011 | US20110212176 Ciclopirox and cytarabine for the treatment of leukemic disorders |
| 09/01/2011 | US20110212168 Composition for targeting dendritic cells |
| 09/01/2011 | US20110212165 Pharmaceutical compositions of the isolated d-enantiomer of the quinazolinone derivative halofuginone |
| 09/01/2011 | US20110212162 Lymphatic zip codes in tumors and pre-malignant lesions |
| 09/01/2011 | US20110212123 Immunogenic Substances Comprising a Polyinosinic Acid - Polycytidilic Acid Based Adjuvant |
| 09/01/2011 | US20110212116 Immunogenic peptides and uses thereof |
| 09/01/2011 | US20110212115 Melk epitope peptides and vaccines containing the same |
| 09/01/2011 | US20110212114 Method for making targeted therapeutic agents |
| 09/01/2011 | US20110212113 Monoclonal Antibody SC104 and Derivative Thereof Specifically Binding to a Sialyltetraosyl Carbohydrate as a Potential Anti-Tumor Therapeutic Agent |
| 09/01/2011 | US20110212110 Compositions and Methods for Detecting TLR3 |
| 09/01/2011 | US20110212108 Neuregulin/erbb signaling and integrin |
| 09/01/2011 | US20110212103 Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
| 09/01/2011 | US20110212102 Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
| 09/01/2011 | US20110212101 Materials and methods for exploiting synthetic lethality in mismatch repair-deficient cancers |
| 09/01/2011 | US20110212098 Novel Melanoma Antigen Peptide and Uses Thereof |
| 09/01/2011 | US20110212096 Anti-p-selectin antibodies and methods of their use and identification |
| 09/01/2011 | US20110212095 Epitope of cd66c specific to lung adenocarcinoma and antibody recognizing the same |
| 09/01/2011 | US20110212094 Dual variable domain immunoglobulins and uses thereof |
| 09/01/2011 | US20110212091 Materials and methods for inhibiting cancer cell invasion |
| 09/01/2011 | US20110212090 Combinatorial Analysis and Repair |
| 09/01/2011 | US20110212089 Targeting pax2 for the treatment of breast cancer |
| 09/01/2011 | US20110212086 GITR Antibodies For The Treatment of Cancer |
| 09/01/2011 | US20110212085 Lung cancer disease targets and uses thereof |
| 09/01/2011 | US20110212079 Adaptive biochemical signatures |
| 09/01/2011 | US20110212077 Bi-aryl meta-pyrimidine inhibitors of kinases |
| 09/01/2011 | US20110212073 Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs |
| 09/01/2011 | US20110212071 Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| 09/01/2011 | US20110212053 Phosphatidylinositol 3 kinase inhibitors |
| 09/01/2011 | US20110212051 Variants of vascular endothelial growth factor (vegf) receptor and use thereof |
| 09/01/2011 | US20110212050 Side-chain crystallizable polymers for medical applications |
| 09/01/2011 | US20110212048 Polymalic acid-based multifunctional drug delivery system |
| 09/01/2011 | US20110212028 Chemically modified cell-penetrating peptides for improved delivery of gene modulating compounds |
| 09/01/2011 | US20110212026 Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system |
| 09/01/2011 | US20110212023 TADG-15: an extracellular serine protease overexpossed in carcinomas |
| 09/01/2011 | US20110212022 Antitumor antibodies, proteins, and uses thereof |
| 09/01/2011 | US20110212021 Targeted oligonucleotide compositions for modifying gene expression |
| 09/01/2011 | US20110209699 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 09/01/2011 | DE102010010666A1 Use of a fatty acid for the diagnostic and/or therapeutic treatment of a cancer e.g. genitourinary cancer, including prostate cancer, colorectal cancer, breast cancer, lung cancer, malignant melanoma, and head and neck carcinoma |
| 09/01/2011 | CA2791162A1 Oxadiazole compounds, their preparation and use |
| 09/01/2011 | CA2791105A1 Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
| 09/01/2011 | CA2791103A1 4 - [cycloalkyloxy (hetero) arylamino] thieno [2,3-d] pyrimidines having mnk1/ mnk2 inhibiting activity for pharmaceutical compositions |
| 09/01/2011 | CA2790577A1 Psma binding ligand-linker conjugates and methods for using |
| 09/01/2011 | CA2790302A1 Dimeric iap inhibitors |
| 09/01/2011 | CA2790199A1 Trimethoxyphenyl inhibitors of tyrosine kinase |
| 09/01/2011 | CA2790014A1 Fully human anti-vegf monoclonal antibody, preparation method and use thereof |
| 09/01/2011 | CA2790007A1 Fully human anti- her2 monoclonal antibody, preparation method and use thereof |
| 09/01/2011 | CA2789789A1 Dna dendrimers as thermal ablation devices |
| 09/01/2011 | CA2787657A1 Compositions and methods for the diagnosis and treatment of tumor |
| 08/31/2011 | EP2361988A1 Molecular marker for cancer stem cell |
| 08/31/2011 | EP2361981A1 RNA sequence-specific mediators of RNA interference |
| 08/31/2011 | EP2361978A1 Polypeptides capable of eliciting an immune reaction against cancer |
| 08/31/2011 | EP2361934A2 Hepatocyte growth factor (HGF) binding proteins |
| 08/31/2011 | EP2361921A2 Novel bicyclonucleoside and oligonnucleotide analogue |
| 08/31/2011 | EP2361920A2 Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity |
| 08/31/2011 | EP2361910A1 Compound having tafia inhibitory activity |
| 08/31/2011 | EP2361907A1 The five crystal forms of the nicousamide, the preparation methods, the pharmaceutical compositions and the uses thereof |
| 08/31/2011 | EP2361905A1 Heterocyclic Inhibitors of MEK and methods of use thereof |
| 08/31/2011 | EP2361903A1 Benzenoid ansamycin derivative |
| 08/31/2011 | EP2361628A1 Pharmaceutical compositions comprising of sodium meta-arsenite for use in the treatment of leukemia and lymphoma |
| 08/31/2011 | EP2361626A1 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
| 08/31/2011 | EP2361624A1 Oxazole derivatives and their use as tyrosine kinase inhibitors |
| 08/31/2011 | EP2361619A1 Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer |
| 08/31/2011 | EP2361306A1 Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms |
| 08/31/2011 | EP2361263A1 Use of anti-cs1 antibodies for treatment of rare lymphomas |
| 08/31/2011 | EP2361254A1 Raf inhibitors and their uses |
| 08/31/2011 | EP2361250A1 Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof |
| 08/31/2011 | EP2361248A1 Heteroaryl compounds and uses thereof |
| 08/31/2011 | EP2361245A1 Hybrid -ionone and curcumin molecules as anticancer agents |
| 08/31/2011 | EP2361242A1 Oxidase inhibitors and their use |
| 08/31/2011 | EP2361086A1 Treatment of oncological diseases |
| 08/31/2011 | EP2361085A2 Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
| 08/31/2011 | EP2214659B1 Use of 4-oxobutanoic acid derivatives in the treatment of pathologies associated with immunological disorders |
| 08/31/2011 | EP2201000B1 Novel imidazole derivatives |
| 08/31/2011 | EP2187915B1 Use of the peptide phpfhlfvy (renin inhibitor) in anti-angiogenic therapy of certain diseases |
| 08/31/2011 | EP2173748B1 Indolyl pyrrolidines for the treatment of cancer |
| 08/31/2011 | EP2173723B1 Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| 08/31/2011 | EP2170891B1 Pyrazolopyrimidinone kinase inhibitor |
| 08/31/2011 | EP2102331B1 Anti-tumor vaccine derived from normal chemically modified cd4+ cells |
| 08/31/2011 | EP2073810B1 Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection |
| 08/31/2011 | EP1361869B1 Transdermal therapeutic system containing testosterone and method for the production thereof |
| 08/31/2011 | EP1079824B1 Triterpene compositions and methods for use thereof |
| 08/31/2011 | CN1895242B Diclofenac salt pleximetric paste and its production |
| 08/31/2011 | CN1659162B Tricyclic thrombin receptor antagonists |
| 08/31/2011 | CN102171340A MELK epitope peptides and vaccines containing the same |
| 08/31/2011 | CN102171249A Long-acting interferons and derivatives thereof and methods thereof |
| 08/31/2011 | CN102171210A Imidazopyridin-2-on derivative |
| 08/31/2011 | CN102171209A Inhibitors of IAP |
| 08/31/2011 | CN102171204A 8-substituted isoquinoline derivative and use thereof |
| 08/31/2011 | CN102171202A Pyridine and pyrimidine based compounds as WNT signaling pathway inhibitors for the treatment of cancer |
| 08/31/2011 | CN102171187A PSMA-binding agents and uses thereof |
| 08/31/2011 | CN102171184A Organosulfur compounds, a method of making organosulfur compounds and their use for inhibiting the growth of tumour cells |
| 08/31/2011 | CN102170939A Depsipeptides and their therapeutic use |
| 08/31/2011 | CN102170909A Anti-NOTCH2 antibodies and methods of use |
| 08/31/2011 | CN102170908A Delivery of a CD40 agonist to a tumor draining lymph node of a subject |
| 08/31/2011 | CN102170907A Pharmaceutical composition for treatment and prevention of cancer |
| 08/31/2011 | CN102170901A Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| 08/31/2011 | CN102170900A Novel immunotherapy against several tumors including neuronal and brain tumors |
| 08/31/2011 | CN102170881A 3, 3', 4, 4' -tetrahydroxy-2, 2' -bipyridine-n, n' -dioxides for the treatment of renal cell carcinoma |
| 08/31/2011 | CN102170873A Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
| 08/31/2011 | CN102170866A Encapsulation of lipophilic or amphiphilic therapeutic agents in nano-emulsions |